Pharmaceuticals

After an investigation by the Center for Public Integrity and NPR into conflicts of interest in Medicaid decisions about drugs, Arizona's governor added new transparency rules.

Drug companies have infiltrated nearly every part of the process that determines how their drugs will be covered by Medicaid, an investigation by NPR and the Center for Public Integrity finds.

The vast amount of data held in electronic medical records and insurance bills contains bits that could be useful in refining the use of approved for drugs. But how to find it?

The pharmaceutical company says it will delay price increases that went into effect on July 1. The move follows pressure from President Trump.

Researchers are looking to redeploy drugs used for years to treat cholesterol and high blood pressure as remedies for influenza and Ebola.

ProPublica found that drugmakers spent less to market opioids to doctors in 2016 than in prior years. Studies have shown that payments to doctors are linked to more prescriptions for the drugs.

A Harvard Medical School project aims to become the first national registry for exceedingly rare cancer patients who respond mysteriously well to treatments that failed to help others.

With 113 locations in the U.S., Brain Balance says its drug-free approach has helped tens of thousands of children. But experts say there's insufficient proof of its effectiveness.

The civil lawsuit is just one of many the opioid drug manufacturer now faces — but the complaint filed Tuesday adds an unusual wrinkle: It also singles out the Sackler family, which owns Purdue.

Legislation that would give terminally ill people a direct path to get experimental treatments raises questions about how the Food and Drug Administration would safeguard patients.

An antibody-based drug reduces the frequency of migraine headaches, according to data reviewed by the Food and Drug Administration. The agency approved Aimovig, priced at about $6,900 a year.

Celgene Corp. has thwarted rival drugmakers eager to make cheaper versions of medicines for a form of blood cancer. Now administration officials are criticizing practices they say hold generics back.